• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型 2019 冠状病毒:基因组结构、临床试验及待解决问题。

Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions.

机构信息

Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Maxim Integrated Products Inc., Chandler, AZ 85225, USA.

出版信息

Exp Biol Med (Maywood). 2020 Jun;245(11):964-969. doi: 10.1177/1535370220920540. Epub 2020 Apr 19.

DOI:10.1177/1535370220920540
PMID:32306751
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7327953/
Abstract

Early availability of the sequence, the genetic material of SARS-CoV-2 (the virus that causes COVID-19), has prompted efforts towards identifying a safe and effective vaccine in the current public health emergency. To that end, understanding the pathophysiology of disease is crucial for scientists around the world. Since conventional vaccine development and manufacturing may take several years, it is important to think about alternative strategies that we could use to mitigate imminent catastrophe. We hope that this article will open up new avenues and provide insights that could potentially save hundreds of lives affected by COVID-19.

摘要

序列的早期获得,即引发 COVID-19 的 SARS-CoV-2 病毒的遗传物质,促使人们在当前的公共卫生紧急情况下努力识别安全有效的疫苗。为此,了解疾病的病理生理学对于全世界的科学家来说至关重要。由于常规疫苗的开发和制造可能需要数年时间,因此考虑使用其他策略来减轻迫在眉睫的灾难非常重要。我们希望本文能开辟新途径并提供潜在的见解,从而有可能拯救数以百计受到 COVID-19 影响的生命。

相似文献

1
Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions.新型 2019 冠状病毒:基因组结构、临床试验及待解决问题。
Exp Biol Med (Maywood). 2020 Jun;245(11):964-969. doi: 10.1177/1535370220920540. Epub 2020 Apr 19.
2
Understanding of COVID-19 based on current evidence.基于现有证据对 COVID-19 的理解。
J Med Virol. 2020 Jun;92(6):548-551. doi: 10.1002/jmv.25722. Epub 2020 Mar 5.
3
Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.具有治疗新型呼吸道 2019 冠状病毒潜力的化合物。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.00399-20.
4
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).2019新型冠状病毒(2019-nCoV)的治疗选择。
Nat Rev Drug Discov. 2020 Mar;19(3):149-150. doi: 10.1038/d41573-020-00016-0.
5
Coronavirus Disease (COVID-19) Pandemic: A Race Against Time.冠状病毒病(COVID-19)大流行:与时间赛跑
Curr Top Med Chem. 2020;20(16):1434-1437. doi: 10.2174/1568026620999200413145654.
6
Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.COVID-19/SARS-CoV-2 在头五个月的科学研究进展。
J Cell Mol Med. 2020 Jun;24(12):6558-6570. doi: 10.1111/jcmm.15364. Epub 2020 May 7.
7
COVID-2019: update on epidemiology, disease spread and management.2019冠状病毒病:流行病学、疾病传播及管理的最新情况
Monaldi Arch Chest Dis. 2020 Apr 16;90(1). doi: 10.4081/monaldi.2020.1292.
8
A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance.羟氯喹维持治疗期间突破性 COVID-19 感染 1 例
J Korean Med Sci. 2020 Jun 22;35(24):e231. doi: 10.3346/jkms.2020.35.e231.
9
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.支持瑞德西韦治疗新型冠状病毒感染的论据。
Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.
10
[Remdesivir, the antiviral hope against SARS-CoV-2].[瑞德西韦,对抗新型冠状病毒的抗病毒希望]
Rev Esp Quimioter. 2020 Jun;33(3):176-179. doi: 10.37201/req/028.2020. Epub 2020 Apr 1.

引用本文的文献

1
RNA-Based Therapies in Kidney Diseases.基于RNA的肾脏疾病治疗方法
J Inflamm Res. 2025 Mar 4;18:3143-3160. doi: 10.2147/JIR.S505252. eCollection 2025.
2
MoMo30 Binds to SARS-CoV-2 Spike Variants and Blocks Infection by SARS-CoV-2 Pseudovirus.莫莫 30 结合 SARS-CoV-2 刺突变异株并阻断 SARS-CoV-2 假病毒感染。
Viruses. 2024 Sep 7;16(9):1433. doi: 10.3390/v16091433.
3
Effect of COVID-19 on healthcare workers' morbidity and mortality compared to the general population in Kohgiluyeh and Boyer-Ahmad Province, Iran.与伊朗科吉卢耶-博韦艾哈迈德省普通人群相比,2019冠状病毒病对医护人员发病率和死亡率的影响。

本文引用的文献

1
On the origin and continuing evolution of SARS-CoV-2.关于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的起源及持续进化
Natl Sci Rev. 2020 Jun;7(6):1012-1023. doi: 10.1093/nsr/nwaa036. Epub 2020 Mar 3.
2
The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020.2019新型冠状病毒病(COVID-19)疫情的流行病学特征 - 中国,2020年
China CDC Wkly. 2020 Feb 21;2(8):113-122.
3
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.SARS-CoV-2 主蛋白酶的晶体结构为设计改良的 α-酮酰胺抑制剂提供了基础。
Health Sci Rep. 2022 Dec 12;6(1):e961. doi: 10.1002/hsr2.961. eCollection 2023 Jan.
4
COVID-19 and diabetes: What do we know so far?新型冠状病毒肺炎与糖尿病:目前我们了解多少?
Exp Biol Med (Maywood). 2022 Aug;247(15):1330-1334. doi: 10.1177/15353702221108914. Epub 2022 Jul 27.
5
Clinical-Epidemiology Aspect of Inpatients With Moderate or Severe COVID-19 in a Brazilian Macroregion: Disease and Countermeasures.巴西大地区中重度 COVID-19 住院患者的临床流行病学:疾病与对策。
Front Cell Infect Microbiol. 2022 May 20;12:899702. doi: 10.3389/fcimb.2022.899702. eCollection 2022.
6
Convalescent serum-derived exosomes: Attractive niche as COVID-19 diagnostic tool and vehicle for mRNA delivery.恢复期血清衍生的外泌体:作为 COVID-19 诊断工具和 mRNA 递送载体的有吸引力的研究领域。
Exp Biol Med (Maywood). 2022 Jul;247(14):1244-1252. doi: 10.1177/15353702221092984. Epub 2022 May 13.
7
Novel antiviral effects of chloroquine, hydroxychloroquine, and green tea catechins against SARS CoV-2 main protease (Mpro) and 3C-like protease for COVID-19 treatment.氯喹、羟氯喹和绿茶儿茶素对严重急性呼吸综合征冠状病毒2型主要蛋白酶(Mpro)和3C样蛋白酶的新型抗病毒作用用于治疗新型冠状病毒肺炎。
Clin Nutr Open Sci. 2022 Apr;42:62-72. doi: 10.1016/j.nutos.2021.12.004. Epub 2022 Jan 28.
8
Is COVID-19-associated cytokine storm distinct from non-COVID-19 secondary hemophagocytic lymphohistiocytosis?COVID-19 相关细胞因子风暴是否与非 COVID-19 继发性噬血细胞性淋巴组织细胞增生症不同?
Exp Biol Med (Maywood). 2022 Feb;247(4):330-337. doi: 10.1177/15353702211068840. Epub 2022 Jan 22.
9
COVID-19 vaccine candidates and vaccine development platforms available worldwide.全球可用的COVID-19候选疫苗和疫苗开发平台。
J Pharm Anal. 2021 Dec;11(6):675-682. doi: 10.1016/j.jpha.2021.09.004. Epub 2021 Sep 14.
10
Identification of evolutionarily stable functional and immunogenic sites across the SARS-CoV-2 proteome and greater coronavirus family.鉴定 SARS-CoV-2 蛋白质组和更大的冠状病毒家族中进化稳定的功能和免疫原性位点。
Bioinformatics. 2021 Nov 18;37(22):4033-4040. doi: 10.1093/bioinformatics/btab406.
Science. 2020 Apr 24;368(6489):409-412. doi: 10.1126/science.abb3405. Epub 2020 Mar 20.
4
Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1.与严重急性呼吸综合征冠状病毒1(SARS-CoV-1)相比,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)在气溶胶和表面的稳定性
N Engl J Med. 2020 Apr 16;382(16):1564-1567. doi: 10.1056/NEJMc2004973. Epub 2020 Mar 17.
5
Epidemiology of COVID-19 Among Children in China.中国儿童 COVID-19 流行病学。
Pediatrics. 2020 Jun;145(6). doi: 10.1542/peds.2020-0702. Epub 2020 Mar 16.
6
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)进入细胞依赖于 ACE2 和 TMPRSS2,可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
7
The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.严重急性呼吸综合征相关冠状病毒:将 2019-nCoV 进行分类并命名为 SARS-CoV-2。
Nat Microbiol. 2020 Apr;5(4):536-544. doi: 10.1038/s41564-020-0695-z. Epub 2020 Mar 2.
8
World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19).世界卫生组织宣布全球紧急状态:对 2019 年新型冠状病毒(COVID-19)的回顾。
Int J Surg. 2020 Apr;76:71-76. doi: 10.1016/j.ijsu.2020.02.034. Epub 2020 Feb 26.
9
Responding to Covid-19 - A Once-in-a-Century Pandemic?应对新冠疫情——一场百年一遇的大流行病?
N Engl J Med. 2020 Apr 30;382(18):1677-1679. doi: 10.1056/NEJMp2003762. Epub 2020 Feb 28.
10
An interactive web-based dashboard to track COVID-19 in real time.一个基于网络的交互式仪表盘,用于实时追踪新冠病毒。
Lancet Infect Dis. 2020 May;20(5):533-534. doi: 10.1016/S1473-3099(20)30120-1. Epub 2020 Feb 19.